BioLine Rx Ltd ADR BLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
-
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
-
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
-
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
-
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
-
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $3.47
- Day Range
- $3.37–3.60
- 52-Week Range
- $2.15–5.27
- Bid/Ask
- $3.28 / $3.45
- Shares Outstanding
- 4.35M
- Market Cap
- $14.66M
- Volume/Avg
- 1 / 48,868
Key Statistics
- Price/Earnings (Normalized)
- 15.18
- Price/Sales
- 10.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.biolinerx.com
Valuation
|
Metric
|
BLRX
|
|---|---|
Price/Earnings (Normalized) | 15.18 |
Price/Book Value | 1.17 |
Price/Sales | 10.66 |
Price/Cash Flow | — |
Price/Earnings
BLRX
Financial Strength
|
Metric
|
BLRX
|
|---|---|
Quick Ratio | 1.41 |
Current Ratio | 1.58 |
Interest Coverage | −8.97 |
Quick Ratio
BLRX
Profitability
|
Metric
|
BLRX
|
|---|---|
Return on Assets (Normalized) | −25.78% |
Return on Equity (Normalized) | −69.14% |
Return on Invested Capital (Normalized) | −32.77% |
Return on Assets
BLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Xhmblwx | Jkpdkrb | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hqlybhvqy | Jfwjtm | $64B | |||
| argenx SE ADR
ARGX
| Vyjfgqxs | Jbdht | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jjgnkrkx | Pbksxcz | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Nwwhngjbcw | Yfpskd | $24B | |||
| BioNTech SE ADR
BNTX
| Trxyszys | Czxys | $23B | |||
| Incyte Corp
INCY
| Qgywldzd | Ldqdy | $22B | |||
| Moderna Inc
MRNA
| Drhjjqpmx | Sqck | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Ppltbmdb | Hlll | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Bfqgxprb | Dgsp | $13B |
United States